<DOC>
	<DOCNO>NCT02176200</DOCNO>
	<brief_summary>Study compare lung oropharyngeal deposition Berodual® ( fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff ) deliver via Respimat® inhaler dose Berodual® deliver via hydrofluoroalkane ( HFA ) - meter dose inhaler ( 2 x puff ) COPD patient different inspiratory flow rate .</brief_summary>
	<brief_title>Respimat® Inhaler v Metered Dose Inhaler Using Berodual® Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable , mild severe airway obstruction force expiratory volume one second ( FEV1 ) ≤70 % predict normal FEV1 ≤70 % force vital capacity ( FVC ) . Predicted normal value calculate accord evolutionary conserve chromosome segment ( ECCS ) Male nonpregnant/nonlactating female patient age ≥18 year All patient must sign informed consent form prior participation study , i.e . prior prestudy washout usual pulmonary medication Current exsmokers smoke history &gt; 10 pack year Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients frequent exacerbation could expect interfere patient 's ability participate study exclude . The enrolment patient exacerbation within six week prior plan study entry postpone . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion exclude Patients recent history ( i.e . six month less ) myocardial infarction Patients unstable lifethreatening cardiac arrhythmia hospitalise heart failure within past year Patients regularly use daytime oxygen therapy 1 hour per day investigator 's opinion unable abstain use oxygen therapy Patients know active tuberculosis Patients history cancer within last five year . Patients treat basal cell carcinoma allow Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion 1 Patients upper respiratory infection past 14 day prior screen visit baseline period lower respiratory tract infection within last 3 month Patients currently pulmonary rehabilitation programme complete pulmonary rehabilitation programme six week prior screen visit Patients know hypersensitivity β2agonists , anticholinergic drug excipients active placebo Berodual® Patients know narrowangle glaucoma Patients treat cromolyn sodium nedocromil sodium Patients treat antihistamine ( H1 receptor antagonist ) Patients use oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose excess equivalent 10 mg prednisolone per day 20 mg every day Patients treat monamine oxidase inhibitor tricyclic antidepressant Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e . oral injectable eg DepoProvera Noristerat contraceptive , intrauterine device , diaphragm plus spermicide subdermal implant eg : Norplant® ) Patients , opinion investigator , history and/or active significant alcohol drug abuse Patients take investigational drug within four month six half life ( whichever great ) prior screen visit and/or administration radiolabelled dosage form within three month prior screen visit Radiation exposure clinical study , include present study diagnostic Xrays exclude background radiation , exceed 5 millisievert ( mSv ) last 12 month 10 mSv last five year . No patient whose occupational exposure monitor participate study Precautions : As anticholinergic drug , Berodual® use caution patient prostatic hyperplasia bladder neck obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>